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Abstract
Background
Rotavirus is the most common cause of  severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy 
of  the rotavirus vaccine in African children.
Methods
We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of  the total) and Malawi (1773 
infants; 35.9% of  the total) to evaluate the efficacy of  a live, oral rotavirus vaccine in preventing severe rotavirus gastroenteritis. Healthy 
infants were randomly assigned in a 1:1:1 ratio to receive two doses of  vaccine (in addition to one dose of  placebo) or three doses of  
vaccine — the pooled vaccine group — or three doses of  placebo at 6, 10, and 14 weeks of  age. Episodes of  gastroenteritis caused by 
wild-type rotavirus during the first year of  life were assessed through active follow-up surveillance and were graded with the use of  the 
Vesikari scale.
Results
A total of  4939 infants were enrolled and randomly assigned to one of  the three groups; 1647 infants received two doses of  the vaccine, 
1651 infants received three doses of  the vaccine, and 1641 received placebo. Of  the 4417 infants included in the per-protocol efficacy 
analysis, severe rotavirus gastroenteritis occurred in 4.9% of  the infants in the placebo group and in 1.9% of  those in the pooled vaccine 
group (vaccine efficacy, 61.2%; 95% confidence interval, 44.0 to 73.2). Vaccine efficacy was lower in Malawi than in South Africa (49.4% 
vs. 76.9%); however, the number of  episodes of  severe rotavirus gastroenteritis that were prevented was greater in Malawi than in South 
Africa (6.7 vs. 4.2 cases prevented per 100 infants vaccinated per year). Efficacy against all-cause severe gastroenteritis was 30.2%. At least 
one serious adverse event was reported in 9.7% of  the infants in the pooled vaccine group and in 11.5% of  the infants in the placebo 
group.
Conclusions
Human rotavirus vaccine significantly reduced the incidence of  severe rotavirus gastroenteritis among African infants during the first 
year of  life. (ClinicalTrials.gov number, NCT00241644.)
Introduction
Rotavirus is the most important cause of  severe gastroenteritis 
among children worldwide. The World Health Organization 
(WHO) estimates that globally 527,000 deaths occur each year 
among children as a result of  rotavirus infection1; more than 
230,000 of  the deaths occur in sub-Saharan Africa. Six of  the 
seven countries with the highest mortality due to rotavirus 
diarrhea are located in Africa.2 Similarly, data generated from 
global rotavirus surveillance networks highlight the burden 
of  hospitalizations for rotavirus3; among young children 
hospitalized for acute diarrhea, the median detection rate for 
rotavirus was 40% globally and 41% in Africa. Therefore, 
measures to prevent rotavirus diarrhea in African children 
are urgently needed.
Vaccines represent the best hope for preventing the 
severe consequences of  rotavirus infection, especially in 
impoverished regions where resources and access to care 
may be limited. Two oral, live attenuated rotavirus vaccines, 
Rotarix (GlaxoSmithKline Biologicals) and RotaTeq 
(Merck), have shown excellent protective efficacy against 
severe rotavirus gastroenteritis in trials conducted mainly 
in Latin America, Europe, and the United States.4-6 The 
WHO’s Strategic Advisory Group of  Experts (SAGE) 
first reviewed data on these vaccines in 2005 and strongly 
recommended the inclusion of  rotavirus vaccination in the 
national immunization programs of  countries and regions 
in which, according to available data, severe rotavirus 
gastroenteritis has a substantial public health impact.7 But 
SAGE noted that live oral vaccines may not be as effective 
in protecting the poorest children in developing countries 
as they are in protecting children in industrialized countries 
and therefore recommended that efficacy trials be conducted 
in representative populations in Africa and Asia before the 
recommendation is extended.1,7 In response to this mandate, 
we conducted a clinical trial to determine whether Rotarix, 
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an attenuated human rotavirus vaccine containing a G1P[8] 
strain, could protect African children against severe rotavirus 
gastroenteritis.
Methods
Study design and participants
We conducted a double-blind, randomized, placebo-
controlled multicenter study in South Africa and Malawi to 
assess the efficacy, safety, and immunogenicity of  Rotarix. 
A placebo-controlled design was chosen because the 
vaccine was not licensed or available in these countries at 
the time the study was initiated, and data were needed to 
inform policy decisions in low-resource countries. Children 
who were infected with human immunodeficiency virus 
(HIV) and children who had been exposed to HIV were 
included in the trial on the basis of  the absence of  serious 
immunosuppression in infants at the age at which these 
vaccines are first given (6 weeks), the experience with other 
live vaccines in HIV-infected children, and the need to inform 
decisions on the introduction of  vaccine in settings with high 
prevalences of  HIV. The study protocol and the informed 
consent form were approved by the ethics committee at 
the WHO and by the ethics committees at all study centers. 
The trial was conducted in accordance with Good Clinical 
Practice guidelines. The parents or legal representatives 
of  the infants participating in the study provided written 
informed consent before the initiation of  any study-related 
procedures. All the investigators shared responsibility for 
the design of  the study and the accrual and analysis of  the 
data. All the authors participated in the preparation of  the 
manuscript and made the decision to submit the manuscript 
for publication.
In South Africa, healthy infants, 5 to 10 weeks of  age, were 
enrolled from October 2005 through January 2006 and from 
November 2006 through early February 2007, before the 
anticipated rotavirus seasons of  2006 and 2007, respectively.8,9 
Since rotavirus is known to circulate year-round in Malawi,10 
infants in Malawi were enrolled from October 2006 through 
July 2007.
Infants were randomly assigned individually, in a 1:1:1 ratio, 
into three groups to receive two doses of  the rotavirus vaccine 
at 10 and 14 weeks of  age; three doses of  the vaccine at 6, 
10, and 14 weeks of  age; or three doses of  placebo. Infants 
in the two-dose vaccine group received a dose of  placebo 
at 6 weeks of  age. Vaccines that are administered routinely 
according to the guidelines of  the Expanded Program on 
Immunization (EPI) were concomitantly administered with 
the vaccine or placebo. No restrictions were imposed on the 
breast-feeding of  infants around the time of  vaccination.
Testing for HIV
The parents or legal representatives of  the infants were given 
the opportunity to have the infants tested for HIV at the 
time the first dose of  vaccine or placebo was administered 
or 1 month after the last dose, and testing was performed 
when consent was given. Detailed information regarding 
the testing and treatment of  infants is included in the 
Supplementary Appendix, available with the full text of  this 
article at NEJM.org.
Vaccine
The study vaccine, the calcium carbonate buffer, and 
the placebo were developed and manufactured by 
GlaxoSmithKline Biologicals. The composition of  the 
vaccine was the same as the commercial formulation, and the 
placebo was the same formulation without the viral antigen.11
Analysis of stool samples during episodes of 
gastroenteritis
An episode of  gastroenteritis was identified by the occurrence 
of  diarrhea, whether or not it was accompanied by vomiting; 
diarrhea was defined as the passage of  three or more stools 
that were looser than normal within a 24-hour period. Stool 
samples were collected during each episode of  gastroenteritis 
that occurred between the date the first dose of  vaccine or 
placebo was administered and the date the child reached 1 
year of  age. Stool samples were tested for rotavirus with 
the use of  an enzyme-linked immunosorbent assay (ELISA) 
(Rotaclone, Meridian Bioscience). All stool samples that were 
positive for rotavirus were examined further with the use of  
a reverse-transcriptase–polymerase-chain-reaction (PCR) 
assay, followed by a reverse hybridization assay to determine 
the G and P types.12
Assessment of vaccine efficacy
The efficacy of  the vaccine was assessed during the period 
from 2 weeks after the last dose of  vaccine or placebo was 
administered until the child reached 1 year of  age. Active 
surveillance for all gastroenteritis episodes was conducted by 
members of  the study staff  through weekly visits to parents 
or guardians to collect diary cards and through the collection 
of  data from health clinics that served the study populations. 
The severity of  each episode of  gastroenteritis was evaluated 
with the use of  the Vesikari scale13 (on which scores range 
from 1 to 20, with higher scores indicating greater severity) 
and was categorized as severe if  the score was 11 or more.
Assessment of safety
All serious adverse events including deaths were recorded 
for the period between the date the first dose of  vaccine 
or placebo was administered and the date the child reached 
1 year of  age. The site investigator, who was unaware of  
the group assignments of  the children, determined whether 
the serious adverse events appeared to have any causal 
association with vaccination.
Assessment of immunogenicity
Blood samples were collected from approximately 10% of  
the infants immediately before the first dose of  vaccine 
or placebo was administered and from all infants 1 month 
after the last dose to determine the serum concentrations of  
antirotavirus IgA antibody. The blood samples were analyzed 
with the use of  an ELISA (GlaxoSmithKline Biologicals), 
with the assay cutoff  point set at 20 U per milliliter.14
Statistical analysis
The primary study analysis compared findings from the 
pooled vaccine group with those from the placebo group. 
The secondary end points were the efficacy of  each vaccine 
dose (i.e., the two-dose vaccine and the three-dose vaccine) 
as compared with placebo. A supplementary analysis was 
performed to evaluate the efficacy, immunogenicity, and 
safety of  the vaccine according to country.
Infants who had received the complete vaccination course 
and had entered the efficacy surveillance period, which began 
2 weeks after the last dose, were included in the prespecified 
primary efficacy analysis (per-protocol efficacy cohort). 
Infants in the pooled vaccine and placebo groups who 
had at least one episode of  severe rotavirus gastroenteritis 
caused by wild-type rotavirus strains during the period from 
2 weeks after the last dose was administered until the infants 
reached 1 year of  age were considered as having achieved the 
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Efficacy
Severe gastroenteritis caused by circulating rotavirus was 
detected in 70 of  1443 infants in the placebo group (4.9%) 
as compared with 56 of  2974 infants in the pooled vaccine 
group (1.9%), resulting in a vaccine efficacy against the 
primary outcome of  severe rotavirus gastroenteritis of  
61.2% (95% confidence interval [CI], 44.0 to 73.2; P<0.001) 
(Table 1). Vaccination with the rotavirus vaccine prevented 
5.0 episodes of  severe rotavirus gastroenteritis per 100 
infant-years (Table 2). The vaccine showed efficacy against 
severe rotavirus gastroenteritis both in infants who received 
two doses of  vaccine (58.7% efficacy; 95% CI, 35.7 to 74.0) 
and in those who received three doses (63.7% efficacy; 
95% CI, 42.4 to 77.8). In South Africa, the efficacy of  the 
vaccine was 76.9% (95% CI, 56.0 to 88.4), and in Malawi 
the vaccine efficacy was 49.4% (95% CI, 19.2 to 68.3); 4.2 
and 6.7 episodes of  severe rotavirus gastroenteritis per 100 
infant-years were prevented by vaccination in South Africa 
and Malawi, respectively (Table 1 and Table 2). The efficacy 
of  the rotavirus vaccine against rotavirus gastroenteritis of  
any severity is presented in Table 2 in the Supplementary 
Appendix.
The distribution of  rotavirus G and P types differed between 
South Africa and Malawi (Figure 1 in the Supplementary 
Appendix). The G1P[8] strain was detected in 57.0% of  the 
primary outcome. The efficacy analysis was also performed 
on data from the total cohort, which included infants who 
received at least one dose of  vaccine or placebo. The safety 
analysis was performed on data from the total cohort. The 
immunogenicity analysis was performed on data from infants 
in the per-protocol efficacy cohort for whom immunogenicity 
data were available. The method used to calculate the sample 
size and specific information about the statistical analysis are 
shown in the Supplementary Appendix.
Results
Study population
A total of  4939 infants were enrolled and randomly assigned 
to one of  three groups (Figure 1); 1647 infants were assigned 
to the two-dose group, 1651 to the three-dose group (for 
a total of  3298 in pooled vaccine group), and 1641 to the 
placebo group. A total of  4417 infants were included in the 
primary efficacy analysis — 2974 in the pooled vaccine group 
and 1443 in the placebo group. The reasons for withdrawal 
from the study are listed in Figure 1. The demographic 
characteristics of  the infants and the proportion of  children 
who were infected with HIV were similar across the study 
groups. Almost all infants (≥99%) received oral poliovirus 
vaccine concomitantly with each dose of  rotavirus vaccine 
or placebo (Table 1 in the Supplementary Appendix).
Th e  new england journal  o f  medicine
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the sample size and specific information about 
the statistical analysis are shown in the Supple-
mentary Appendix.
Results
Study Population
A total of 4939 infants were enrolled and ran-
domly assigned to one of three groups (Fig. 1); 
1647 infants were assigned to the two-dose 
group, 1651 to the three-dose group (for a total 
of 3298 in pooled vaccine group), and 1641 to 
the placebo group. A total of 4417 infants were 
included in the primary efficacy analysis — 2974 
in the pooled vaccine group and 1443 in the pla-
cebo group. The reasons for withdrawal from 
the study are listed in Figure 1. The demograph-
ic characteristics of the infants and the propor-
tion of children who were infected with HIV were 
similar across the study groups. Almost all in-
fants (≥99%) received oral poliovirus vaccine 
concomitantly with each dose of rotavirus vac-
cine or placeb  (Table 1 i  the Supplem ntary 
ppendix).
7 col
39p6
4939 (99.9%) Underwent randomization
and were included in the safety analysis
4941 Infants were assessed for eligibility
2 Withdrew consent
3298 Were assigned to receive
rotavirus vaccine
1641 Were assigned to receive
placebo
495 Were withdrawn
90 Had a serious adverse event
1 Had a nonserious adverse event
8 Had a protocol violation
133 Withdrew consent (not owing to
adverse event)
115 Relocated
143 Were lost to follow-up
62 Had incomplete vaccination course
81 Had complete vaccination course
5 Had other reasons
249 Were withdrawn
44 Had a serious adverse event
1 Had a nonserious adverse event
4 Had a protocol violation
79 Withdrew consent (not owing to
adverse event)
53 Relocated
63 Were lost to follow-up
29 Had incomplete vaccination course
34 Had complete vaccination course
5 Had other reasons
324 Were excluded from the efficacy analysis
264 Were not administered at least one
dose
23 Contracted concomitant infection by
rotavirus strain other than the vaccine
strain up to 2 wk after dose 3 (which
may influence efficacy response)
21 Were not administered study vaccine
dose as per protocol
11 Were not entered into the follow-up
surveillance period
5 Had broken randomization code
198 Were excluded from the efficacy analysis
140 Were not administered at least one
dose
39 Contracted concomitant infection by
rotavirus strain other than the vaccine
strain up to 2 wk after dose 3 (which
may influence efficacy response)
8 Were not administered study vaccine
dose as per protocol
10 Were not entered into the follow-up
surveillance period
1 Had broken randomization code
2974 (90.1%) Were included in the
efficacy analysis
1443 (87.9%) Were included in the
efficacy analysis
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Figure 1. Study Assignment and Follow-up.
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episodes among recipients of  the placebo in South Africa 
and in 12.9% of  the episodes among recipients of  the 
placebo in Malawi. The type-specific efficacy against severe 
rotavirus gastroenteritis and the difference in incidence 
rates between the vaccine groups and the placebo group are 
shown in Table 1 and Table 2, respectively.
The incidence rate of  severe gastroenteritis from any cause 
was 8.6% in the pooled vaccine group as compared with 
12.3% in the placebo group, corresponding to a reduction 
in the rate with vaccination of  30.2% (95% CI, 15.0 to 42.6;
P<0.001) (Table 3). The reductions in all-cause severe 
gastroenteritis were statistically significant in both countries. 
The efficacy of  the vaccine in the total vaccinated cohort 
was similar to that in the per-protocol efficacy cohort (Tables 
3 to 6 in the Supplementary Appendix).
Safety
At least one serious adverse event occurred during the study 
period in 319 of  the 3298 infants in the pooled vaccine group 
(9.7%; 95% CI, 8.7 to 10.7) and in 189 of  the 1641 infants 
in the placebo group (11.5%; 95% CI, 10.0 to 13.2) (Table 
7 in the Supplementary Appendix). During the entire study 
period, 83 deaths occurred among infants in the pooled 
vaccine group (2.5%; 95% CI, 2.0 to 3.1) and 43 deaths 
occurred among those in the placebo group (2.6%; 95% 
CI, 1.9 to 3.5). A single case of  intussusception occurred 11 
weeks after the third dose of  rotavirus vaccine in a 6-month-
old child who was assigned to the three-dose vaccine group. 
The child underwent bowel resection and recovered fully. 
Three adverse events were judged by the investigators to 
be related to vaccination — two cases of  sepsis and one of  
otitis media.
Immunogenicity
At 1 month after the last dose of  vaccine was administered, 
the seroconversion rates for antirotavirus IgA in South 
Africa were 57.1% (95% CI, 44.7 to 68.9) in the two-dose 
group and 66.7% (95% CI, 54.0 to 77.8) in the three-dose 
group. The seroconversion rates in Malawi were 47.2% (95% 
CI, 30.4 to 64.5) in the two-dose group and 57.1% (95% CI, 
42.2 to 71.2) in the three-dose group. In the placebo group, 
the seropositivity rates for antirotavirus IgA at 1 month after 
the last dose were 16.7% (95% CI, 14.2 to 19.5) in South 
Africa and 40.4% (95% CI, 34.9 to 46.1) in Malawi.
Discussion
This study shows that a live, oral rotavirus vaccine 
significantly reduces the episodes of  severe rotavirus 
gastroenteritis in African children during the first year of  life. 
The attack rate for severe rotavirus gastroenteritis was higher 
in these populations than has been reported in other studies 
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Efficacy
Severe gastroenteritis caused by circulating rota-
virus was detected in 70 of 1443 infants in the 
placebo group (4.9%) as compared with 56 of 
2974 infants in the pooled vaccine group (1.9%), 
resulting in a vaccine efficacy against the primary 
outcome of severe rotavirus gastroenteritis of 
61.2% (95% confidence interval [CI], 44.0 to 73.2; 
P<0.001) (Table 1). Vaccination with the rotavirus 
vaccine prevented 5.0 episodes of severe rotavirus 
gastroenteritis per 100 infant-years (Table 2). The 
vaccine showed efficacy against severe rotavirus 
gastroenteritis both in infants who received two 
doses of vaccine (58.7% efficacy; 95% CI, 35.7 to 
74.0) and in those who received three doses (63.7% 
efficacy; 95% CI, 42.4 to 77.8). In South Africa, 
the efficacy of the vaccine was 76.9% (95% CI, 
56.0 to 88.4), and in Malawi the vaccine efficacy 
was 49.4% (95% CI, 19.2 to 68.3); 4.2 and 6.7 epi-
sodes of severe rotavirus gastroenteritis per 100 
infant-years were prevented by vaccination in South 
Africa and Malawi, respectively (Tables 1 and 2). 
The efficacy of the rotavirus vaccine against ro-
tavirus gastroenteritis of any severity is presented 
in Table 2 in the Supplementary Appendix.
The distribution of rotavirus G and P types 
Table 1. Efficacy of Rotavirus Vaccine with Respect to the Development of Severe Rotavirus Gastroenteritis and Hospitalization for Rotavirus 
Gastroenteritis.*
Variable Infants with at Least One Event Vaccine Efficacy P Value†
Rotavirus Vaccine Placebo
no./total no.  % (95% CI) no./total no. % (95% CI) % (95% CI)
Severe rotavirus gastroenteritis
Overall
Pooled 56/2974 1.9 (1.4–2.4) 70/1443 4.9 (3.8–6.1) 61.2 (44.0–73.2) <0.001
Two-dose 30/1496 2.0 (1.4–2.9) — — 58.7 (35.7–74.0) <0.001
Three-dose 26/1478 1.8 (1.2–2.6) — — 63.7 (42.4–77.8) <0.001
Malawi
Pooled 41/1030 4.0 (2.9–5.4) 38/483 7.9 (5.6–10.6) 49.4 (19.2–68.3) 0.003
Two-dose 21/525 4.0 (2.5–6.0) — — 49.2 (11.1–71.7) 0.01
Three-dose 20/505 4.0 (2.4–6.1) — — 49.7 (11.3–72.2) 0.01
South Africa
Pooled 15/1944 0.8 (0.4–1.3) 32/960 3.3 (2.3–4.7) 76.9 (56.0–88.4) <0.001
Two-dose 9/971 0.9 (0.4–1.8) — — 72.2 (40.4–88.3) <0.001
Three-dose 6/973 0.6 (0.2–1.3) — — 81.5 (55.1–93.7) <0.001
Rotavirus-type–specific severe rota - 
virus gastroenteritis‡
Overall
G1 strain 17/2974 0.6 (0.3–0.9) 23/1443 1.6 (1.0–2.4) 64.1 (29.9–82.0) 0.002
Non-G1 strain 39/2974 1.3 (0.9–1.8) 47/1443 3.3 (2.4–4.3) 59.7 (37.1–74.4) <0.001
Malawi
G1 strain 6/1030 0.6 (0.2–1.3) 5/483 1.0 (0.3–2.4) 43.7 (<0–85.7) 0.34
Non-G1 strain 35/1030 3.4 (2.4–4.7) 33/483 6.8 (4.7–9.5) 50.3 (17.4–70.0) 0.005
South Africa
G1 strain 11/1944 0.6 (0.3–1.0) 18/960 1.9 (1.1–2.9) 69.8 (32.5–87.1) 0.002
Non-G1 strain 4/1944 0.2 (0.1–0.5) 14/960 1.5 (0.8–2.4) 85.9 (55.1–96.6) <0.001
Hospitalization for rotavirus  
gastroenteritis‡
14/2974 0.5 (0.3–0.8) 16/1443 1.1 (0.6–1.8) 57.5 (7.2–80.8) 0.02
* A total of 4417 infants were included in the efficacy analysis — 2974 in the pooled vaccine group and 1443 in the placebo group.
† P values were calculated with the use of a two-sided Fisher’s exact test. P values of less than 0.05 were considered to indicate a statistically 
significant difference.
‡ Data in the rotavirus vaccine group are for the pooled vaccine cohort.
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of  rotavirus vaccines.4,5 Because of  this high incidence of  
severe disease, a vaccine efficacy of  61.2% resulted in a 
substantial vaccine-attributable reduction in severe rotavirus 
gastroenteritis (reduction of  5.0 cases per 100 infant-years). 
In addition, the rotavirus vaccine was associated with a 
reduction in all-cause severe gastroenteritis of  30.2%. 
This reduction in the incidence of  the disease occurred in 
a trial that was designed to simulate real-world conditions 
of  use; thus, the rotavirus vaccine is expected to deliver a 
considerable public health benefit when it is introduced into 
similar settings.
The overall efficacy of  the rotavirus vaccine in preventing 
episodes of  severe rotavirus gastroenteritis (61.2%) was 
lower than that observed in European studies and Latin 
American studies (96.4% and 84.8%, respectively), which 
included some low- to middle-income countries.4-6,15 This 
finding is consistent with findings from other studies of  
live oral vaccines, such as the oral poliovirus vaccine,16 
the cholera vaccine,17 oral typhoid vaccines,18 and earlier 
rotavirus vaccines,19 none of  which were as immunogenic 
or effective in populations in developing countries as they 
were in populations in industrialized countries. Several 
mechanisms have been proposed to explain why live oral 
rotavirus vaccines may not be as efficacious in populations 
of  infants from low-income countries.20 Possible reasons 
include host characteristics, such as poor nutritional status 
and enteric coinfections; levels of  antirotavirus antibodies 
in breast milk; and interference by maternal antibody or by 
coadministration of  the oral poliovirus vaccine, which may 
reduce rotavirus antibody levels.21,22 The potential role of  
these and other factors will be important to elucidate, in 
order to further improve the performance of  these vaccines 
in populations where they are most needed.
The efficacy of  the rotavirus vaccine in Malawian infants 
in this study was lower than that in their South African 
counterparts (49.4% vs. 76.9%). In addition to potential 
Th e  new england journal  o f  medicine
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differed between South Africa and Malawi (Fig. 1 
in the Supplementary Appendix). The G1P[8] strain 
was detected in 57.0% of the episodes among 
recipients of the placebo in South Africa and in 
12.9% of the episodes among recipients of the 
placebo in Malawi. The type-specific efficacy 
against severe rotavirus gastroenteritis and the 
difference in incidence rates between the vaccine 
groups and the placebo group are shown in Ta-
ble 1 and Table 2, respectively.
The incidence rate of severe gastroenteritis 
from any cause was 8.6% in the pooled vaccine 
group as compared with 12.3% in the placebo 
group, corresponding to a reductio  n the rate 
with v ation of 30.2% (95% CI, 15.0 to 42.6; 
P<0.001) (Table 3). The reductions in all-cause 
severe gastr enteritis were statistically signifi-
cant in both countries. The efficacy of the vac-
cine in the total vaccinated cohort was similar to 
that in the per-protocol efficacy cohort (Tables 
3 to 6 in the Supplementary Appendix).
Safety
At least one serious adverse event occurred dur-
ing the study period in 319 of the 3298 infants in 
the pooled vaccine group (9.7%; 95% CI, 8.7 to 
10.7) and in 189 of the 1641 infants in the pla-
cebo group (11.5%; 95% CI, 10.0 to 13.2) (Table 
7 in the Supplementary Appendix). During the 
entire study period, 83 deaths occurred among 
infants in the pooled vaccine group (2.5%; 95% 
CI, 2.0 to 3.1) and 43 deaths occurred among 
t ose in the placebo group (2.6%; 95% CI, 1.9 to 
3.5). A single ase of intussusception occur d 11 
weeks af er the third dose of rotavirus vaccine in 
a 6-mo th- ld child who was assigned to the 
three-dose vaccin group. The child underwe t 
b wel esection and recovered fully. Three adverse 
Table 2. Risk of Severe Rotavirus Gastroenteritis in the Pooled Vaccine Group and the Placebo Group, According to 
Dose, Country, and Rotavirus Strain.*
Cohort Rotavirus Vaccine Placebo
Difference in Rate
(95% CI)†
No. in  
Cohort
Episodes/ 
100 Infants/Yr
(95% CI)
No. in  
Cohort
Episodes/ 
100 Infants/Yr
(95% CI)
Severe rotavirus gastroenteritis
Pooled 2974 3.0 (2.3–3.9) 1443 8.0 (6.3–10.1) 5.0 (3.1–7.2)
Two-dose 1496 3.2 (2.2–4.6) — — 4.8 (2.6–7.1)
Three-dose 1478 2.8 (1.9–4.1) — — 5.2 (3.0–7.5)
Country‡
Malawi 1030 6.5 (4.8–8.8) 483 13.1 (9.6–18.0) 6.7 (2.4–11.9)
South Africa 1944 1.2 (0.7–2.0) 960 5.4 (3.8–7.7) 4.2 (2.4–6.5)
Rotavirus type‡
Total cohort 2974 1443
G1 strain 0.9 (0.6–1.5) 2.6 (1.7–3.9) 1.7 (0.6–3.0)
Non-G1 strain 2.1 (1.5–2.9) 5.3 (4.0–7.1) 3.2 (1.7–5.1)
Malawi 1030 483
G1 strain 0.9 (0.4–2.1) 1.7 (0.7–4.0) 0.7 (<0–3.1)
Non-G1 strain 5.5 (4.0–7.7) 11.3 (8.1–16.0) 5.8 (1.9–10.7)
South Africa 1944 960
G1 strain 0.9 (0.5–1.6) 3.0 (1.9–4.8) 2.1 (0.8–3.9)
Non-G1 strain 0.3 (0.1–0.9) 2.4 (1.4–4.0) 2.0 (0.9–3.7)
* The analyses are based on the efficacy cohort, which comprised 4417 infants — 2974 in the pooled vaccine group and 
1443 in the placebo group.
† The difference in rate is calculated as the episodes per 100 infants per year in the placebo group minus the episodes 
per 100 infants per year in the rotavirus vaccine group.
‡ Data in the rotavirus vaccine group are for the pooled vaccine cohort.
The New England Journal of Medicine 
Downloaded from nejm.org by Andrew Mataya on August 24, 2016. For personal u e only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants
n engl j med 362;4 nejm.org january 28, 2010 295
events were judged by the investigators to be re-
lated to vaccination — two cases of sepsis and 
one of otitis media.
Immunogenicity
At 1 month after the last dose of vaccine was 
administered, the seroconversion rates for anti-
rotavirus IgA in South Africa were 57.1% (95% 
CI, 44.7 to 68.9) in the two-dose group and 66.7% 
(95% CI, 54.0 to 77.8) in the three-dose group. 
The seroconversion rates in Malawi were 47.2% 
(95% CI, 30.4 to 64.5) in the two-dose group and 
57.1% (95% CI, 42.2 to 71.2) in the three-dose 
group. In the placebo group, the seropositivity 
rates for antirotavirus IgA at 1 month after the 
last dose were 16.7% (95% CI, 14.2 to 19.5) in 
South Africa and 40.4% (95% CI, 34.9 to 46.1) in 
Malawi.
DISCUSSION
This study shows that a live, oral rotavirus vac-
cine significantly reduces the episodes of severe 
rotavirus gastroenteritis in African children dur-
ing the first year of life. The attack rate for severe 
rotavirus gastroenteritis was higher in these pop-
ulations than has been reported in other studies 
of rotavirus vaccines.4,5 Because of this high inci-
dence of severe disease, a vaccine efficacy of 61.2% 
resulted in a substantial vaccine-attributable re-
duction in severe rotavirus gastroenteritis (reduc-
tion of 5.0 cases per 100 infant-years). In addition, 
the rotavirus vaccine was associated with a reduc-
tion in all-cause severe gastroenteritis of 30.2%. 
This reduction in the incidence of the disease oc-
curred in a trial that was designed to simulate 
real-world conditions of use; thus, the rotavirus 
vaccine is expected to deliver a considerable pub-
lic health benefit when it is introduced into sim-
ilar settings.
The overall efficacy of the rotavirus vaccine in 
preventing episodes of severe rotavirus gastroen-
teritis (61.2%) was lower than that observed in 
European studies and Latin American studies 
(96.4% and 84.8%, respectively), which included 
some low- to middle-income countries.4-6,15 This 
finding is consistent with findings from other 
studies of live oral vaccines, such as the oral 
poliovirus vaccine,16 the cholera vaccine,17 oral ty-
phoid vaccines,18 and earlier rotavirus vaccines,19 
none of which were as immunogenic or effective 
in populations in developing countries as they 
were in populations in industrialized countries. 
Several mechanisms have been proposed to ex-
plain why live oral rotavirus vaccines may not be 
as efficacious in populations of infants from low-
income countries.20 Possible reasons include host 
characteristics, such as poor nutritional status 
and enteric coinfections; levels of antirotavirus 
antibodies in breast milk; and interference by 
maternal antibody or by coadministration of the 
oral poliovirus vaccine, which may reduce rota-
virus antibody levels.21,22 The potential role of 
these and other factors will be important to elu-
cidate, in order to further improve the perfor-
mance of these vaccines in populations where 
they are most needed.
The efficacy of the rotavirus vaccine in Mala-
wian infants in this study was lower than that in 
their South African counterparts (49.4% vs. 
76.9%). In addition to potential differences men-
tioned above, rotavirus circulation differs in the 
two countries (a winter–spring peak in South 
Africa8,9 as compared with year-round circulation 
in Malawi10), and that difference was reflected in 
the study enrollment strategies (preceding the 
Table 3. Efficacy of R tavirus Va cine against All-Cause Severe Gastroenteritis.*
Cohort Infants with at Least One Event of All-Cause Severe Gastroenteritis Vaccine Efficacy P Value†
Rotavirus Vaccine Placebo
no./total no. % (95% CI) no./total no. % (95% CI) % (95% CI)
Ov rall 256/2974 8.6 (7.6–9.7) 178/1443 12.3 (10.7–14.1) 30.2 (15.0–42.6) <0.001
Malawi 187/1030 18.2 (15.8–20.6) 117/483 24.2 (20.5–28.3) 25.1 4.7–40.8) 0.007
South Africa 69/1944 3.5 (2.8–4.5) 61/960 6.4 (4.9–8.1) 44.1 (19.8–61.0) <0.001
* The analyses are based on the efficacy cohort, which comprised 4417 infants — 2974 in the pool d vaccine group and 
1443 in the placebo group.
† P values were calculated with the use of a two-sided Fisher’s exact test. P values of less than 0.05 were considered to 
indicate a statistically significant difference.
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differences mentioned above, rotavirus circulation differs in 
the two countries (a winter–spring peak in South Africa8,9 as 
compared with year-round circulation in Malawi10), and that 
difference was reflected in the study enrollment strategies 
(preceding the rotavirus season in South Africa as compared 
with year-round in Malawi). The rotavirus seropositivity rate 
among placebo recipients 1 month after the last dose had 
been given was greater among Malawian infants than among 
South African infants (40.4% vs. 16.7%), suggesting that 
Malawian infants have high exposure to wild-type rotavirus 
infection in the first 5 months of  life. Since infection with wild-
type rotavirus confers protection against the development 
of  severe rotavirus disease later in infancy,23 the greater 
exposure of  the infants in the placebo group in Malawi to 
rotavirus infection before their entry into the follow-up 
period may have lowered the estimate of  vaccine efficacy 
in Malawi. Despite the lower point estimate for efficacy, 
the number of  severe cases of  rotavirus gastroenteritis 
prevented was greater in Malawi than in South Africa (6.7 vs. 
4.2 cases prevented per 100 infant-years), owing to the higher 
incidence of  severe rotavirus gastroenteritis in Malawi.
In this study, the diversity of  the circulating strains was 
striking. In Malawi, only 12.9% of  the rotavirus strains were 
G1P[8] — the strain on which this vaccine is based, and the 
most commonly occurring strain globally.24,25 A substantial 
proportion of  G2, G8, G9, and G12 strains were isolated 
during the course of  this study. Rotavirus types G2, G8, and 
G9 have circulated for several years in both countries, whereas 
rotavirus type G12 has been reported more recently.26,27 
It is unlikely, however, that these differences in strains 
contributed to the lower vaccine efficacy, since the efficacy 
against G1 and non-G1 severe rotavirus gastroenteritis was 
similar. These data are consistent with an integrated analysis 
of  previous efficacy trials of  the rotavirus vaccine, which 
indicates that the rotavirus vaccine provides protection 
against severe rotavirus gastroenteritis caused by G1 and 
non-G1 strains.28 The ability of  a rotavirus vaccine to protect 
against a wide panel of  strains is important in Africa, where 
the diversity of  rotavirus strains is substantial.24,25,29
We did not detect significant differences in vaccine 
immunogenicity or efficacy between the cohort receiving two 
vaccine doses and the cohort receiving three doses, although 
this study was not powered to detect such differences. 
There was a slight but nonsignificant trend toward higher 
seroconversion rates and vaccine efficacy with the three-dose 
schedule. It should be noted that in the two-dose schedule 
used in this study, the doses of  vaccine were administered at 
the second and third childhood vaccine visit, when the infants 
were an average of  11 and 16 weeks of  age, respectively. 
Outside the setting of  a clinical trial, a two-dose schedule 
in which the rotavirus vaccine is administered at the second 
and third childhood vaccination visits is not practical, since 
it is recommended that the first dose of  rotavirus vaccine 
be delivered before the infant is 12 weeks of  age, owing to 
lingering concerns stemming from the age-dependent risk 
of  intussusception associated with a previous rotavirus 
vaccine.1 Since children in developing countries frequently 
present late for vaccination visits,30 this age restriction would 
deny many children the opportunity to receive the rotavirus 
vaccine if  it were recommended at a later visit. Although a 
two-dose schedule in which the vaccine is administered at 
the first and second childhood vaccination visits is a more 
practical option, such a schedule was not tested in this study. 
Administering rotavirus vaccines at younger ages could lower 
the immunogenicity of  the vaccines, because of  the potential 
for greater interference of  maternal antibody20 and enhanced 
replication of  the oral poliovirus vaccine.22,31,32 It will be 
important to undertake studies to assess the effectiveness of  
two doses of  rotavirus vaccine administered at earlier ages 
than those at which they were administered in this study.
The WHO’s Global Advisory Committee on Vaccine Safety 
(GACVS) has reviewed the safety of  the currently licensed 
rotavirus vaccines33,34 and has concluded that in clinical trials 
of  these vaccines, no association was seen between receipt 
of  the vaccines and an increased risk of  intussusception. 
Further, postmarketing surveillance data show that an 
intussusception risk that is of  a similar magnitude to that 
which had been associated with a previous rotavirus vaccine, 
Rotashield (Wyeth–Lederle), is unlikely.34,35 The single case 
of  intussusception in this trial was not temporally related to 
rotavirus vaccination, and the rate of  serious adverse events 
did not differ between infants who received the vaccine and 
those who received the placebo. Continuing surveillance of  
the safety of  the vaccines as they are introduced into more 
countries will be important.
On the basis of  this study and other supporting data, 
SAGE recently recommended that rotavirus vaccination of  
infants be included in all national immunization programs, 
in conjunction with other proven interventions for diarrheal 
disease.36 Appropriate financing mechanisms that will 
allow ministries of  health in Africa to bring this potentially 
lifesaving vaccine to the children in greatest need are urgently 
needed.
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